On September 13, the State Council Information Office held a press conference in Beijing focused on “Promoting High-Quality Development.” During this event, Li Li, the Director of the National Medical Products Administration (NMPA), emphasized the agency’s commitment to enhancing dynamic oversight throughout the entire drug lifecycle. He outlined three primary priorities: risk prevention, case investigation, and capacity enhancement, which are integral to ensuring drug safety and fostering public trust.
Li highlighted the NMPA’s strong support for centralized procurement of pharmaceuticals and medical devices at the national level. To facilitate this initiative, the agency conducts rigorous inspections of manufacturing companies and implements 100% sampling inspections on selected products, aiming to balance price reductions with uncompromised product quality.
He also reported on the ongoing progress in assessing the quality and efficacy consistency of generic drugs, revealing that two-thirds of commonly used chemical drugs have already been evaluated.
From January to August this year, the NMPA conducted a total of 20,969 drug inspections, achieving an impressive pass rate of 99.43%. This statistic reflects a stable overall safety situation for pharmaceuticals and bolsters confidence in the country’s drug safety measures.
